• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EORTC QLQ-C30 评估晚期癌症患者总体生活质量的预测因素。

Predictive factors of overall quality of life in advanced cancer patients using EORTC QLQ-C30.

机构信息

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):139-46. doi: 10.1586/14737167.2014.864560. Epub 2013 Dec 10.

DOI:10.1586/14737167.2014.864560
PMID:24325545
Abstract

OBJECTIVE

To identify which domains/symptoms from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) were predictive of overall quality of life (QoL) in advanced cancer patients.

METHODS

Four hundred and forty seven patients with brain metastases or bone metastases from seven countries were enrolled with regression analysis to determine the predictive value of the QLQ-C30 functional/symptom scores for patient reported overall QoL (question 30), overall health (question 29) and the global health status domain (questions 29 and 30).

RESULTS

Worse role functioning, social functioning, fatigue and financial problems were the most significant predictive factors for worse QoL. In the bone metastases subgroup (n = 400), role functioning, fatigue and financial problems were the most significant predictors. In patients with brain metastases (n = 47), none of the EORTC domains significantly predicted worse QOL.

CONCLUSION

Deterioration of certain QLQ-C30 functional/symptom scores significantly contributes to worse QoL, overall health and global health status.

摘要

目的

确定欧洲癌症研究与治疗组织生存质量问卷核心 30 问卷(EORTC QLQ-C30)的哪些领域/症状与晚期癌症患者的整体生存质量(QoL)相关。

方法

从 7 个国家的 447 名脑转移或骨转移患者中进行回归分析,以确定 QLQ-C30 功能/症状评分对患者报告的整体 QoL(问题 30)、整体健康(问题 29)和全球健康状况领域(问题 29 和 30)的预测价值。

结果

较差的角色功能、社会功能、乏力和经济问题是 QoL 较差的最显著预测因素。在骨转移亚组(n=400)中,角色功能、乏力和经济问题是最重要的预测因素。在脑转移患者中(n=47),EORTC 各领域均未显著预测 QOL 较差。

结论

QLQ-C30 某些功能/症状评分的恶化显著导致 QoL、整体健康和全球健康状况的恶化。

相似文献

1
Predictive factors of overall quality of life in advanced cancer patients using EORTC QLQ-C30.EORTC QLQ-C30 评估晚期癌症患者总体生活质量的预测因素。
Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):139-46. doi: 10.1586/14737167.2014.864560. Epub 2013 Dec 10.
2
Predictive factors for overall quality of life in patients with advanced cancer.晚期癌症患者总体生活质量的预测因素。
Support Care Cancer. 2013 Jun;21(6):1709-16. doi: 10.1007/s00520-013-1717-7. Epub 2013 Jan 22.
3
Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL.脑转移瘤患者的生活质量评估:EORTC QLQ-BN20+2 与 QLQ-C15-PAL 联合应用。
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1238-45. doi: 10.1016/j.ijrobp.2011.09.025. Epub 2011 Dec 13.
4
Predictive factors of overall well-being using the EORTC QLQ-C15-PAL extracted from the EORTC QLQ-C30.基于 EORTC QLQ-C30 提取的 EORTC QLQ-C15-PAL 评估总体幸福感的预测因素。
J Palliat Med. 2013 Apr;16(4):402-8. doi: 10.1089/jpm.2012.0398. Epub 2013 Mar 4.
5
The EORTC QLQ-OH17: a supplementary module to the EORTC QLQ-C30 for assessment of oral health and quality of life in cancer patients.EORTC QLQ-OH17:EORTC QLQ-C30 的补充模块,用于评估癌症患者的口腔健康和生活质量。
Eur J Cancer. 2012 Sep;48(14):2203-11. doi: 10.1016/j.ejca.2012.04.003. Epub 2012 May 8.
6
Quality of life in patients with primary and metastatic brain cancer as reported in the literature using the EORTC QLQ-BN20 and QLQ-C30.文献中使用 EORTC QLQ-BN20 和 QLQ-C30 报告的原发性和转移性脑癌患者的生活质量。
Expert Rev Pharmacoecon Outcomes Res. 2012 Dec;12(6):831-7. doi: 10.1586/erp.12.70.
7
Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.使用欧洲癌症研究与治疗组织核心生活质量问卷(QLQ-C30)对韩国样本中接受癌症疼痛管理的晚期患者的生活质量变化进行评估。
Oncology. 2008;74 Suppl 1:7-12. doi: 10.1159/000143212. Epub 2008 Aug 28.
8
The assessment of health-related quality of life and related factors in Chinese elderly patients undergoing chemotherapy for advanced cancer: a cross-sectional study.中国老年晚期癌症化疗患者健康相关生活质量及其相关因素评估:一项横断面研究。
Eur J Oncol Nurs. 2014 Aug;18(4):425-35. doi: 10.1016/j.ejon.2014.03.005. Epub 2014 Apr 8.
9
Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ-BM22.姑息性放射治疗骨转移疼痛患者的生活质量:验证 EORTC QLQ-BM22 的国际研究结果。
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e337-42. doi: 10.1016/j.ijrobp.2012.05.028. Epub 2012 Jul 3.
10
Comparison of the EORTC QLQ-BM22 and the BOMET-QOL quality of life questionnaires in patients with bone metastases.骨转移患者中欧洲癌症研究与治疗组织QLQ - BM22问卷与BOMET - QOL生活质量问卷的比较。
Asia Pac J Clin Oncol. 2014 Jun;10(2):118-23. doi: 10.1111/ajco.12064. Epub 2013 Apr 1.

引用本文的文献

1
Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.阿贝西利联合非甾体芳香化酶抑制剂或氟维司群用于激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌女性患者:随机III期MONARCH plus试验的最终结果
Chin Med J (Engl). 2024 Oct 10. doi: 10.1097/CM9.0000000000003151.
2
Patient and Caregiver Perceptions of Advanced Bladder Cancer Systemic Treatments: Infodemiology Study Based on Social Media Data.患者及照护者对晚期膀胱癌全身治疗的认知:基于社交媒体数据的信息流行病学研究
JMIR Cancer. 2023 Mar 27;9:e45011. doi: 10.2196/45011.
3
Are gastrointestinal problems, nutritional care, and nutritional care needs associated with quality of life in patients with advanced cancer? Results of the observational eQuiPe study.
胃肠道问题、营养护理以及营养护理需求是否与晚期癌症患者的生活质量相关?观察性 eQuiPe 研究的结果。
Support Care Cancer. 2023 Feb 27;31(3):189. doi: 10.1007/s00520-023-07646-1.
4
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.一项随机试验的两年结果:比较4周一次与12周一次使用骨靶向药物治疗乳腺癌或去势抵抗性前列腺癌骨转移患者的疗效
J Bone Oncol. 2021 Sep 2;30:100388. doi: 10.1016/j.jbo.2021.100388. eCollection 2021 Oct.
5
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.一项比较骨转移乳腺癌或去势抵抗性前列腺癌患者接受 4 周和 12 周骨靶向药物治疗的随机临床试验。
Eur J Cancer. 2021 Jan;142:132-140. doi: 10.1016/j.ejca.2020.08.019. Epub 2020 Oct 3.